Rhaeos, Inc

About Rhaeos, Inc

Rhaeos is a company focused on improving the detection of shunt malfunctions in hydrocephalus patients through innovative technology. Their mission is to address the challenges in assessing hydrocephalus shunt flow, reducing emergency department visits, readmissions, and healthcare costs.

Products & Services

FlowSense:A non-invasive, wireless, wearable device that assesses hydrocephalus shunt flow in minutes.

Specialties

Hydrocephalus treatment Medical devices Non-invasive diagnostics

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Grant T: - FT: Grant	A: 1500000 MR: - FA: $1.5 million FAN: 1500000	D: 2023-10-09 FD: 2023-10-09	1 investors
2	RT: Series A T: - FT: Series A	A: 10500000 MR: - FA: $10.5 million FAN: 10500000	D: 2023-02-16 FD: 2023-02-16	3 investors

Grant Latest

2023-10-09

$1.5M

1 investor (Pro only)

Series A 2023-02-16

$10.5M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

A

Anna Lisa Somera

Chief Executive Officer

J

John Rogers

Co-Founder, President

R

R. Chad Webb

Chief Technology Officer

A

Adam Zysk

Chief Innovation Officer

D

David D. Limbrick, Jr.

Chief Medical Officer

J

John Adair

Fractional CFO

View 24 more team members with Pro

Unlock Full Team Directory

Recent News

Rhaeos, Inc Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised